BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2635 related articles for article (PubMed ID: 7901150)

  • 1. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.
    Kern DE; Klarnet JP; Jensen MC; Greenberg PD
    J Immunol; 1986 Jun; 136(11):4303-10. PubMed ID: 2422280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activation of L3T4+ helper T cells assisting the generation of anti-tumor Lyt-2+ cytotoxic T lymphocytes: requirement of Ia-positive antigen-presenting cells for processing and presentation of tumor antigens.
    Kosugi A; Yoshioka T; Suda T; Sano H; Takahama Y; Fujiwara H; Hamaoka T
    J Leukoc Biol; 1987 Dec; 42(6):632-41. PubMed ID: 2960766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of MHC class I-restricted CD8+ CTL by microbial T cell mitogens. Dependence upon MHC class II expression of the target cells and V beta usage of the responder T cells.
    Herrmann T; Maryanski JL; Romero P; Fleischer B; MacDonald HR
    J Immunol; 1990 Feb; 144(4):1181-6. PubMed ID: 1968075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic T lymphocyte precursor cells specific for the major histocompatibility complex class I-like antigen, Qa-2, require CD4+ T cells to become primed in vivo and to differentiate into effector cells in vitro.
    Muraoka S
    Eur J Immunol; 1991 Sep; 21(9):2095-103. PubMed ID: 1679712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production.
    McMenamin C; Holt PG
    J Exp Med; 1993 Sep; 178(3):889-99. PubMed ID: 8102390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accessory cell requirements for saponin adjuvant-induced class I MHC antigen-restricted cytotoxic T-lymphocytes.
    Wu JY; Gardner BH; Kushner NN; Pozzi LA; Kensil CR; Cloutier PA; Coughlin RT; Newman MJ
    Cell Immunol; 1994 Apr; 154(1):393-406. PubMed ID: 7907530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses.
    Olsen AC; Fossum B; Kirkin AF; Zeuthen J; Gaudernack G
    Scand J Immunol; 1995 Apr; 41(4):357-64. PubMed ID: 7899823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
    Tomita Y; Mayumi H; Eto M; Nomoto K
    J Immunol; 1990 Mar; 144(6):2425-35. PubMed ID: 1968930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4-CD8- T cell receptor alpha beta T cells: generation of an in vitro major histocompatibility complex class I specific cytotoxic T lymphocyte response and allogeneic tumor rejection.
    Mieno M; Suto R; Obata Y; Udono H; Takahashi T; Shiku H; Nakayama E
    J Exp Med; 1991 Jul; 174(1):193-201. PubMed ID: 1905338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
    Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
    Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of class I and class II MHC-restricted antigen presentation by cytotoxic T lymphocytes specific for an exogenous antigen.
    Rock KL; Rothstein L; Fleischacker C; Gamble S
    J Immunol; 1992 May; 148(10):3028-33. PubMed ID: 1578128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
    Homma S; Komita H; Sagawa Y; Ohno T; Toda G
    Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of T-T lymphocytes and T-accessory cell interactions using cloned T cells: MHC I restricted cloned T cells activate MHC II restricted T helper cells.
    Brückner T; Di Pauli R
    Cell Immunol; 1986 Apr; 99(1):182-95. PubMed ID: 2875800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interplay between the TCR/CD3 complex and CD4 or CD8 in the activation of cytotoxic T lymphocytes.
    de Vries JE; Yssel H; Spits H
    Immunol Rev; 1989 Jun; 109():119-41. PubMed ID: 2527803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
    Yoshimura A; Shiku H; Nakayama E
    J Immunol; 1993 Jun; 150(11):4900-10. PubMed ID: 8496592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo.
    Lee RS; Grusby MJ; Glimcher LH; Winn HJ; Auchincloss H
    J Exp Med; 1994 Mar; 179(3):865-72. PubMed ID: 8113680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
    Marzo AL; Lake RA; Robinson BW; Scott B
    Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of allo-class II MHC-specific Th2 cells on the generation of CD4 and CD8 cytotoxic T cells to associated class I and class II MHC alloantigen.
    Wood PJ; Cossens IA
    Clin Exp Immunol; 1995 May; 100(2):359-65. PubMed ID: 7743677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells.
    Mangino G; Grazia Capri M; Barnaba V; Alberti S
    Int J Cancer; 2002 Oct; 101(4):353-9. PubMed ID: 12209960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 132.